Erik Penser Bank initiates coverage of Idogen
Idogen AB (publ) is developing tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response. In conjunction when the company is about to enter clinical phase with its most advanced development program IDO 8, Erik Penser Bank (EPB) has initiated coverage of Idogen and has published its initiation analysis of Idogen AB. The company has currently focus on areas where there are large unmet medical needs – like e.g. Hemophilia A where patients have developed antibodies against its vital treatment with factor VIII. Another example is